|
AstraZeneca PLC on Tuesday declared a higher total dividend, as it posted increased revenue and profit for 2025 and hailed its ‘harmonised listing structure’ following its recent debut on the New York Stock Exchange. The Cambridge, England-based pharmaceutical company reported pretax profit of $2.63 billion for the fourth quarter of 2025, jumping 58% from $1.67 billion a year earlier. Driving this advance was a top-line gain of 4.1%, as total revenue rose to $15.503 billion from $14.891 billion. Within this, product revenue rose by 10% to $15.497 billion, while collaboration revenue all but disappeared, at $6 million from $815 million. Further supporting earnings were a lower Research & Development expenses in the fourth quarter, down 17% at $3.86 billion from $4.68 billion a year before. For 2025 as a whole, the pharmaceutical company registered a 43% gain in pretax profit to $12.40 billion from $8.69 billion in 2024. As with the final quarter, this was driven by top-line gains, as total revenue advanced 8.6% to $58.74 billion from $54.07 billion. Product revenue grew 10% to $58.64 billion, while collaboration revenue contracted 89% to $99 million. However, unlike in the fourth quarter, AstraZeneca posted a higher R&D expense in all of 2025, as it grew 4.8% to $14.23 billion. AstraZeneca declared a second interim dividend of $2.17 per share, up 3.3% from $2.10 a year earlier. This brought its total dividend for the year to $3.20, up 3.2% from $3.10. ‘In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines,’ said Chief Executive Pascal Soriot. Looking ahead to 2026, AstraZeneca issued guidance at constant exchange rates. It sees total revenue increasing by a mid-to-high single-digit percentage, and core earnings per share rising by a low double-digit percentage. Core EPS in 2025 was $9.16, up 12%. For the fourth quarter it was $2.12, up 1.4%. ‘The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing, including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.’ Shares in AstraZeneca were trading 0.8% higher at 14,000.00 pence per share on Tuesday morning in London. The company recently debuted on the New York Stock Exchange, with its shares up 2.2% at $192.12 in pre-market trading. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
